Hepatocellular Carcinoma Market is Expected to Witness Remarkable Growth During the Study Period (2019-32), Assesses DelveInsight – Yahoo Finance

Hepatocellular Carcinoma market size is anticipated to rise in the coming years owing basically to the increase in the incidence of the population in the 7MM and increased research and development activities as well as the entrance of major pharmaceutical companies working towards the development of potential Hepatocellular Carcinoma therapies.

LAS VEGAS, July 18, 2022 /PRNewswire/ --DelveInsight's Hepatocellular Carcinoma Market Insightsreport proffers a detailed comprehension of the Hepatocellular Carcinoma market size by treatment, epidemiology, emerging therapies, market share of the individual therapies, current and forecasted Hepatocellular Carcinoma market size from 2019 to 2032 segmented into the 7MM (the USA, EU5 ( Germany, France, Italy, Spain, and the UK), and Japan).

DelveInsight Logo

Some of the salient features from the Hepatocellular Carcinoma MarketReport:

DelveInsight analysts suggested that the Hepatocellular Carcinoma market size in the 7MM was is expected to increase drastically owing to the launches of several potential emerging therapies during the study period (2019-2032).

Key Hepatocellular Carcinoma companies such as H3 Biomedicine Inc, Genoscience Pharma, Kymab Limited, Exelixis, CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co, Geneos Therapeutics, Adaptimmune Therapeutics, and othersare reported to bring a significant shift in the Hepatocellular Carcinoma.

The Hepatocellular Carcinoma emerging therapies that are expected to launch in the forecast period include H3B-6527, GNS561, KY1044, Cabozantinib, and others.

DelveInsight's analysts observed that the increase in Hepatocellular Carcinoma market size is a direct consequence of the high incidence of the population in the 7MM.

Also, as per the study, the highest incident Hepatocellular Carcinoma cases were found in the US whereas the least incident Hepatocellular Carcinoma cases were found in Spain in the 7MM countries.

Hepatocellular Carcinoma is now the fifth most common cause of cancer worldwide.

For further information on the market impact by therapies, download the Hepatocellular Carcinoma sample @ Hepatocellular Carcinoma Therapeutic Scenario

Hepatocellular Carcinoma Overview

Hepatocellular Carcinoma is defined as a liver tumor that is not eligible for local therapies given the extent of disease or liver tumors that recurred after local therapies. Hepatocellular Carcinoma patients usually have a significant underlying liver disease which is associated with poor tolerability to systemic chemotherapy. Cancer cells may have spread to nearby lymph nodes and/or to distant sites within the body. Hepatocellular Carcinoma does not often metastasize, but when it does, it's most likely to spread to the lungs and bones. These cancers are widespread and they cannot be removed with surgery. Hepatocellular Carcinoma signs and symptoms are not always directly related to the stage of cancer, the effects of the disease are highly individualized for each person. Some of the Hepatocellular Carcinoma symptoms include Gynecomastia, Erythrocytosis, High cholesterol, Hypercalcemia, and Hypoglycemia. Hepatocellular Carcinoma treatment decisions depend on the size of the cancer and whether it has spread. It also depends on the health of the liver tissue that is not affected by cancer, for example, if the person has liver cirrhosis.

Hepatocellular Carcinoma Epidemiology Segmentation

As per the assessment of DelveInsight, the Hepatocellular Carcinoma incident caseswere found to be approximately 32k cases in the US in the year 2021.

The Hepatocellular Carcinoma Marketreport offers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into

Total Incident Cases of Hepatocellular Carcinoma (HCC)

Stage-wise patients of Hepatocellular Carcinoma (HCC)

Total Treated Cases of Hepatocellular Carcinoma (HCC)

Keen to learn how Hepatocellular Carcinoma Epidemiological Trends are going to appear in 2032 for the 7 MM, Download @ Hepatocellular Carcinoma Epidemiological Insights

Hepatocellular Carcinoma Market Outlook

There are currently more than four FDA-approved immunotherapy options for liver cancer. Several other immunotherapies are currently being tested in clinical trials, including oncolytic viruses and adoptive cell therapy. Hence, the Hepatocellular Carcinoma therapy market includes Bevacizumab (Avastin) a targeted antibody that targets the VEGF-A pathway; approved, in combination with atezolizumab, as a first-line treatment for patients with unresectable or metastatic Hepatocellular Carcinoma. Other therapies include CYRAMZA (ramucirumab) manufactured by Eli Lilly and Company is a VEGFR2 antagonist and is the very first FDA-approved biomarker-driven therapy in patients with Hepatocellular Carcinoma. Pembrolizumab (Keytruda) is a checkpoint inhibitor produced by Merck and approved for subsets of patients with advanced liver cancer. Genentech's product Atezolizumab (Tecentriq) is a checkpoint inhibitor that targets the PD-L1 pathway; approved, in combination with bevacizumab, as a first-line treatment of Hepatocellular Carcinoma for subsets of patients with advanced liver cancer. GSK received FDA approval for Dostarlimab (Jemperli) a checkpoint inhibitor that targets the PD-1/PD-L1 pathway in patients with liver cancer that has DNA mismatch repair deficiency (dMMR). Nivolumab (Opdivo) is produced by Bristol-Myers Squibb Company, it is a checkpoint inhibitor that targets the PD-1/PD-L1 pathway approved for subsets of patients with advanced liver cancer. Another Bristol-Myers Squibb Hepatocellular Carcinoma FDA-approved product is Ipilimumab (Yervoy) a checkpoint inhibitor that targets the CTLA-4 pathway; approved, in combination with nivolumab, for patients with advanced, previously treated liver cancer.

The dynamics of the Hepatocellular Carcinoma market is anticipated to change in the coming years owing to the improvement in the rise in the number of pipeline therapies across the liver cancer area including key players, such as H3 Biomedicine Inc., Genoscience Pharma, Kymab Limited, Exelixis working to develop pipeline therapies such as H3B-6527, GNS561, KY1044, Cabozantinib, and many more in the Hepatocellular Carcinoma pipeline.

Discover more about therapy set to grab substantial Hepatocellular Carcinoma market share @ Hepatocellular Carcinoma Market Trends

Key Hepatocellular Carcinoma Companies and Pipeline Therapies

To know about more Hepatocellular Cancer pipeline therapies covered in the report, visit @ Hepatocellular Carcinoma Pipeline Analysis, Clinical Trials, and Emerging Therapies

Hepatocellular Carcinoma Market Dynamics

The increase in the Hepatocellular Carcinoma market size is a direct consequence of the high incidence population in the 7MM. Also, the increase is due to fact that there are a number of cancer research and developmental activities, as well as increased healthcare spending across the 7MM that will aid in the rise of the Hepatocellular Carcinoma market in the coming years. The increased patient pool and entrance of key pharmaceutical companies working towards the development of potential Hepatocellular Carcinoma therapies in order to fulfill the unmet medical needs of the currently used therapeutics will supposedly boost the Hepatocellular Carcinoma market.

Know which therapy is expected to score the touchdown first @ Hepatocellular Carcinoma Market Landscape and Forecast

Scope of the Hepatocellular Carcinoma Market Report

Study Period: 2019-32

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Hepatocellular Carcinoma Companies: H3 Biomedicine Inc, Genoscience Pharma, Kymab Limited, Exelixis, CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co, Geneos Therapeutics, Adaptimmune Therapeutics

Key Hepatocellular Carcinoma Pipeline Therapies: H3B-6527, GNS561, KY1044, Cabozantinib

Hepatocellular Carcinoma Therapeutic Assessment: Hepatocellular Carcinoma current marketed and emerging therapies

Hepatocellular Carcinoma Dynamics: Hepatocellular Carcinoma drivers and barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Unmet Needs

KOL's views

Analyst's views

Hepatocellular Carcinoma Access and Reimbursement

Request for a Webex demo of the report @Hepatocellular Carcinoma Therapeutics Market

Table of Contents

1

Key Insights

2

Report Introduction

3

Hepatocellular Carcinoma Market Overview at a Glance

4

Executive Summary of Hepatocellular Carcinoma

5

Hepatocellular Carcinoma Epidemiology and Market Methodology

6

Hepatocellular Carcinoma: Disease Background and Overview

7

Diagnosis of Hepatocellular Carcinoma

8

Hepatocellular Carcinoma Treatment

9

Conclusion for Hepatocellular Carcinoma

10

Hepatocellular Carcinoma Epidemiology and Patient Population

11

Hepatocellular Carcinoma Patient Journey

12

Key Endpoints in Hepatocellular Carcinoma Clinical Trials

13

Hepatocellular Carcinoma Marketed Therapies

14

Hepatocellular Carcinoma Emerging Therapies

15

Hepatocellular Carcinoma: 7 Major Market Analysis

16

Market Access and Reimbursement

17

KOL Views

18

Hepatocellular Carcinoma Market Drivers

19

Hepatocellular Carcinoma Market Barriers

20

Hepatocellular Carcinoma SWOT Analysis

21

Hepatocellular Carcinoma Unmet Needs

22

Appendix

23

DelveInsight Capabilities

24

Disclaimer

25

About DelveInsight

Get in touch with our Business executive @Hepatocellular Carcinoma Regulatory and Patent Analysis

Related Reports

Advanced Hepatocellular Carcinoma

DelveInsight's, "Advanced Hepatocellular Carcinoma Pipeline Insight, 2022," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Advanced Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products and key Advanced Hepatocellular Carcinoma companies such as CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, and many others.

Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis

DelveInsight's, "Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis Pipeline Insight, 2022," report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Advanced Hepatocellular Carcinoma with CPB Liver Cirrhosis pipeline landscape. It covers the pipeline drug profiles, including clinical, nonclinical stage products, and key pipeline companies such as Can-Fite Biopharma and others.

Read the original here:
Hepatocellular Carcinoma Market is Expected to Witness Remarkable Growth During the Study Period (2019-32), Assesses DelveInsight - Yahoo Finance